TFF Pharmaceuticals, Inc.

NasdaqCM:TFFP Voorraadrapport

Marktkapitalisatie: US$6.8m

TFF Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

TFF Pharmaceuticals' CEO is Harlan Weisman, appointed in Dec 2022, has a tenure of 1.92 years. total yearly compensation is $2.08M, comprised of 26.5% salary and 73.5% bonuses, including company stock and options. directly owns 0.94% of the company’s shares, worth $64.19K. The average tenure of the management team and the board of directors is 1.9 years and 3.3 years respectively.

Belangrijke informatie

Harlan Weisman

Algemeen directeur

US$2.1m

Totale compensatie

Percentage CEO-salaris26.5%
Dienstverband CEO1.9yrs
Eigendom CEO0.9%
Management gemiddelde ambtstermijn1.9yrs
Gemiddelde ambtstermijn bestuur3.3yrs

Recente managementupdates

Recent updates

Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?

Apr 10
Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?

Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

Sep 27
Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

TFF Pharma: The Potential Is Still Very Much Present

Aug 29

TFF Pharmaceuticals: Q3 Data Is Pivotal In So Many Ways

Aug 09

TFF Pharmaceuticals expands R&D operations with new Austin facility

Jul 14

TFF Pharmaceuticals: A Highly Attractive Basket Of Options

May 23

We Think TFF Pharmaceuticals (NASDAQ:TFFP) Needs To Drive Business Growth Carefully

May 17
We Think TFF Pharmaceuticals (NASDAQ:TFFP) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About TFF Pharmaceuticals' (NASDAQ:TFFP) Cash Burn Situation

Jan 06
Here's Why We're Not Too Worried About TFF Pharmaceuticals' (NASDAQ:TFFP) Cash Burn Situation

TFF Pharmaceuticals: Upside Catalysts Starting To Show Up Amid Omicron, But Timidly

Dec 02

Analyse CEO-vergoeding

Hoe is Harlan Weisman's beloning veranderd ten opzichte van TFF Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$19m

Mar 31 2024n/an/a

-US$20m

Dec 31 2023US$2mUS$550k

-US$21m

Sep 30 2023n/an/a

-US$24m

Jun 30 2023n/an/a

-US$27m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$594kUS$42k

-US$32m

Sep 30 2022n/an/a

-US$34m

Jun 30 2022n/an/a

-US$36m

Mar 31 2022n/an/a

-US$32m

Dec 31 2021US$40kn/a

-US$31m

Sep 30 2021n/an/a

-US$27m

Jun 30 2021n/an/a

-US$23m

Mar 31 2021n/an/a

-US$22m

Dec 31 2020US$241kn/a

-US$19m

Sep 30 2020n/an/a

-US$41m

Jun 30 2020n/an/a

-US$39m

Mar 31 2020n/an/a

-US$38m

Dec 31 2019US$216kn/a

-US$37m

Compensatie versus markt: Harlan's total compensation ($USD2.08M) is above average for companies of similar size in the US market ($USD655.02K).

Compensatie versus inkomsten: Harlan's compensation has increased whilst the company is unprofitable.

CEO

Harlan Weisman (72 yo)

1.9yrs

Tenure

US$2,076,038

Compensatie

Dr. Harlan F. Weisman M.D. is Operating Partner of CR Group L.P. Dr. Weisman was Senior Advisor of CR Group L.P. from 2012. Dr. Weisman is Clinical Advisor of Protagonist Therapeutics, Inc. Dr. Weisman joi...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Harlan Weisman
President1.9yrsUS$2.08m0.94%
$ 64.2k
Kirk Coleman
CFO, Treasurer & Secretary6.8yrsUS$469.07k0.041%
$ 2.8k
Zamaneh Mikhak
Chief Medical Officer1.8yrsUS$865.13k0.16%
$ 10.6k

1.9yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: TFFP's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
Harlan Weisman
President5.9yrsUS$2.08m0.94%
$ 64.2k
Robert Mills
Independent Director6.8yrsUS$144.53k0.065%
$ 4.4k
Stephen Rocamboli
Independent Director5.9yrsUS$67.88k0.042%
$ 2.8k
Anthony Hickey
Chairman of the Scientific Advisory Board and Senior Research & Development Advisor1.8yrsgeen gegevensgeen gegevens
Catherine Lee
Independent Directorless than a yearUS$41.85kgeen gegevens
David Denning
Member of Scientific Advisory Board3.3yrsgeen gegevensgeen gegevens
Brandi Roberts
Independent Director2.7yrsUS$70.92k0.023%
$ 1.6k
Drew Weissman
Member of Scientific Advisory Board3.3yrsgeen gegevensgeen gegevens
Ted Ross
Member of Scientific Advisory Board3.3yrsgeen gegevensgeen gegevens
Mike Saag
Member of Scientific Advisory Board3.3yrsgeen gegevensgeen gegevens
David Cornfield
Member of Scientific Advisory Board3.3yrsgeen gegevensgeen gegevens
Jay Peters
Member of Scientific Advisory Board3.3yrsgeen gegevensgeen gegevens

3.3yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: TFFP's board of directors are considered experienced (3.3 years average tenure).